However, the occurrence of shifts in cytosolic [Ca2+] may not be a general phenomenon, as on-target Bcl-2 inhibitors, like ABT-737127 and venetoclax/ABT-199128, do not trigger these early cytosolic [Ca2+] elevations, even not in cancer cells that are dependent on Bcl-2 for their survival. Here, BCL2 is linked to cancer.